# The Seasonal Influenza Vaccine Cannot Trigger a Titer Increase Among 1 **Some Elderly Individuals** 2 3 4 Authors Yang Ge<sup>1</sup>^\*, Wangnan Cao<sup>2</sup>\*, Shengzhi Sun<sup>3</sup>, Ted M. Ross<sup>4,5</sup>, Ye Shen<sup>6</sup> 5 6 Authors affiliations 7 <sup>1</sup>: School of Health Professions, University of Southern Mississippi, Hattiesburg, 39402, MS, USA; https://orcid.org/0000-0001-5100-0703; <sup>2</sup>: School of Public Health, Peking 8 9 University, Beijing, China; <sup>3</sup>: School of Public Health, Capital Medical University, Beijing, 10 China; <sup>4</sup>: Center for Vaccines and Immunology, The University of Georgia, Athens, 30606, GA, USA; <sup>5</sup>: Cleveland Clinic, Port St. Lucie, 34952, FL, USA; <sup>6</sup>: College of Public Health, The 11 12 University of Georgia, Athens, 30606, GA, USA; https://orcid.org/0000-0002-6662-0048. 13 \* Joint first authors 14 ^ Corresponding authors: <a href="mailto:yang.ge@usm.edu">yang.ge@usm.edu</a>, <a href="mailto:yeshen@uga.edu">yeshen@uga.edu</a> 15 Abstract word count: 47 16 Text word count: 1076 17 **Conflicts of interest**: None of the authors declare any conflicts of interest. 18 **Funding sources**: Yang Ge was supported by the Start-up Grant from the University of 19 Southern Mississippi and NIH contract 75N93019C00052. Wangnan Cao was supported 20 by Beijing Natural Science Foundation (L222029). Ted M. Ross is supported by the Georgia

Research Alliance as an Eminent Scholar. Ye Shen received partial support from NIH
grants/contracts R35GM146612, R01AI170116 and 75N93019C00052. The funders had no
role in the study design, data collection and analysis, decision to publish, or preparation
of the manuscript.

Ethics statement: We conducted a secondary analysis on data collected from an ongoing human vaccine cohort study. The procedures, informed consent, and data collection documents of the cohort study were reviewed and approved by the Western Institutional Review Board and the Institutional Review Boards of the University of Pittsburgh and the University of Georgia.

30 Acknowledgements: The authors would like to thank Hannah Hanley for coordinating 31 the UGA influenza vaccine study, as well as Brittany Baker, Frankie Stewart, and Emma 32 Whitesell for excellent phlebotomy and data entry services. The authors would also like 33 to thank Hana Ji, James Allen, Michael Carlock, Jasmine Burris, Omar Hamwy, Mitchell Lee, 34 Laruen Howland for processing samples and Rosemary Kim, Jasper Gattiker, and Erin 35 Jarrett for performing and virological assays. The authors also thank Brad Phillips and Kim 36 Schmitz from the UGA Clinical and Translation Research Unit for assistance in enrollment 37 and sample collections. Finally, the authors thank all the enrolled participants for 38 providing their time and samples to the study.

40

## Abstract

- 41 Many elderlies exhibited absent responses to influenza vaccines. Our exploration of this
- 42 heterogeneity revealed associations with vaccine dose (HD vs. SD, OR: 0.59 (95%Crl, 0.4
- 43 to 0.87)), pre-vaccination titer levels (OR: 1.57 (95%Crl, 1.38 to 1.8), and gender (Male
- 44 vs. Female OR: 2.12 (95%Crl, 1.38 to 3.25)).
- 45 Key words: Influenza, Vaccine, Titer Increase
- 46 **Data Availability Statement**: The data supporting the findings of this study are
- 47 available upon reasonable request.

4	8
---	---

#### Main text

49 Influenza results in over half a million deaths annually, predominantly among older adults 50 [1,2]. Certain older individuals exhibit a limited or absent response to vaccines, while 51 others do not. Investigating the factors contributing to this disparity can enhance our 52 comprehension of high-risk populations and facilitate the enhancement of vaccination 53 strategies. 54 According to CDC's recommendations [3], adults aged 65 years and older have the option 55 56 to choose a high-dose (HD) influenza vaccine over a standard-dose (SD) one. The licensed 57 SD split-inactivated virion vaccine contains 15 micrograms of HA antigen for each strain. 58 In contrast, Sanofi Pasteur's Fluzone HD provides 60 micrograms of HA for each vaccine 59 strain, showing a relative benefit [4]. It would be intriguing to explore this benefit further, 60 investigating whether the HD vaccine reduces the proportion of older adults with a limited 61 or absent response to vaccines or merely enhances antibody levels in those who respond. 62

We obtained human vaccination data covering the flu seasons from 2014/15 to 2019/20 from our ongoing vaccination cohort study [5,6]. Each year, investigators enrolled individuals who hadn't received an influenza vaccine in the season preceding the flu season's onset. People aged 65 and older were offered a choice between HD and SD vaccines. Serological samples were collected both before vaccination and 21-28 days

68 after. Hemagglutination-inhibition (HAI) antibody levels were assessed using standard 69 dilution assays. Thus, the data has hierarchical features, with individuals repeatedly 70 enrolled in different flu seasons and tested for HAI titers for different homologous strains. 71 The HD vaccine was trivalent during the entire study years, while the SD vaccines were trivalent in 2013 and 2014, but quadrivalent in later years, with the quadrivalent 72 73 formulation containing an additional B-strain. Unlike the SD, the trivalent HD vaccine 74 contained only a single B strain; therefore, in this study, we focused solely on influenza A 75 subtypes and excluded results related to all B strains. Our emphasis was on the 76 homologous HAI titer increase of the vaccine. It was defined as log2 scale of the ratio of 77 the post-vaccination Hemagglutination Inhibition (HAI) titer over the pre-vaccination HAI 78 titer. This outcome signifies the difference between post-vaccination and pre-vaccination 79 titers, providing insight into a participant's immunological response to the vaccine.

80

The HAI titer, obtained through the dilution assay, exhibited discrete positive values, resulting in discrete observations of titer increase. However, a significant number of participants showed no titer increase after vaccination, leading to an excess of zeros and overdispersion in the outcome of titer increase. To address this, we assumed the elderly could be categorized into two sub-populations. The first, **Sensitive to the Influenza Vaccine (SIV)**, included participants with a positive vaccine-induced titer increase. The other, **Insensitive to the Influenza Vaccine (IIV)**, displayed either zero or negative titer increase. The HAI titer, obtained through the dilution assay, had discrete positive values,
 leading to discrete observations of titer increase. Thus, we applied a hurdle Poisson
 regression model to our data.

91

92 Our hurdle Poisson regression model combines a logistic and Poisson process. The logistic 93 process generates zero to represent the IIV sub-population, characterized by zero or 94 negative titer increase. When the logistic process yields one (representing the SIV sub-95 population), the Poisson process is used to model the positive values of titer increase. If 96 we define  $\theta$  as the probability of IIV and  $\lambda$  as the titer increase for SIV, the probability 97 mass function of the hurdle-Poisson model is defined by

98 
$$p(y|\theta,\lambda) = \begin{cases} \theta & \text{if } y = 0, \text{ and} \\ (1-\theta) \frac{\text{Poisson}(y|\lambda)}{1-\text{Poisson}\text{CDF}(0|\lambda)} & \text{if } y > 0, \end{cases}$$

99

To assess the vaccine dose impact (HD vs. SD) while accounting for multilevel features in the study, we used a Bayesian multilevel modeling approach. This included incorporating two random intercepts for repeated enrollment and strains formulated into a single vaccine. Our models also considered age, gender, race, and pre-vaccination titer as covariates. We use mean and credible interval (CrI) to summarize results.

Our samples cover influenza seasons from 2013/14 to 2019/20. During this time, the HD and SD vaccines were given for 564 and 440 times, respectively, to individuals aged 65 years and older (Figure 1A). Both vaccine groups had comparable age and gender distributions, along with similar median pre-vaccination titers below 1:40. Across the entire study period, eight different influenza type A vaccine strains were observed. About one-third of the elderly population did not show a positive titer increase after vaccination, ranging from 6% to 53% (Figure 1B).

113

114 The results of the hurdle-Poisson model are shown in Figure 1C. In comparison to the SD, 115 individuals who received the HD vaccine had an Odds Ratio (OR) of being an IIV as 0.59 116 (95%Crl, 0.4 to 0.87). Additionally, higher pre-vaccination titer and being male had ORs 117 equal to 1.57 (95%Crl, 1.38 to 1.8) and 2.12 (95%Crl, 1.38 to 3.25), respectively. In cases 118 where an individual responded to the influenza vaccine, HD might associate with a small 119 additional titer increase as 0.08 (95%Crl, -0.07 to 0.22). Conversely, higher pre-vaccination 120 titer and being male were associated with a reduced titer increase as -0.23 (95%Crl, -0.28 121 to -0.18) and -0.24 (95%Crl, -0.4 to -0.07), respectively.

122

123 Influenza vaccine effectiveness varies among populations, showing significantly reduced 124 protection (10%) among the elderly [7]. An important reason could be aligned with our 125 findings that many elderly individuals (> 30%) had limited or absent immune responses after vaccination. Our study suggests that the HD vaccine may decrease the likelihood of an elderly individual becoming an IIV, but it has only a mild impact on the actual titer increase if a response is triggered. We also observed that individuals with some preexisting immunities or being male had a worse response to the vaccine than their counterparts.

131

Our study controlled for repeated influenza vaccination and the administration of multiple strains simultaneously in trivalent or quadrivalent vaccines. However, our sample size was not balanced across the seven influenza seasons, and participants were not randomly assigned to HD or SD groups, potentially introducing bias. Additionally, we were not able to further explore why some individuals did not adequately respond to the vaccine due to a lack of detailed health background information.

138

Understanding the mechanism behind how individuals become the IIV population poses a significant challenge, but it is crucial for the development of a universal influenza vaccine [8]. If an influenza vaccine only works on the low-risk population and cannot induce an immune response in high-risk populations (e.g., the elderly), our fight against the impact of the flu remains challenging and arduous. Additional research is warranted to study why the influenza vaccine cannot trigger a titer increase among some elderly individuals.



Figure 1: Data description and hurdle-poisson model outputs. A) Data description; B)
The distribution of titer increase for different vaccine strains. The proportions of Elderly
sub-population were insensitive to the influenza vaccine (IIV) has been calculated. C)
Estimates of the hurdle-poisson model. The left side is the logistic model for estimating

- 150 the associations between variables and the likelihood of being an IIV individual. The
- 151 right side is the Poisson model for estimating the associations between variables and
- 152 the titer increase for an SIV individual.

154		Reference
155	[1]	Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza-
156		associated respiratory mortality: A modelling study. The Lancet. 2018;391:1285-
157		1300.
158	[2]	Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza
159		and respiratory syncytial virus in the United States. JAMA. 2003;289:179–186.
160	[3]	Grohskopf LA. Prevention and Control of Seasonal Influenza with Vaccines:
161		Recommendations of the Advisory Committee on Immunization Practices United
162		States, 2023 Influenza Season. MMWR Recommendations and Reports. 2023;72.
163	[4]	van Aalst R, Gravenstein S, Mor V, et al. Comparative effectiveness of high dose
164		versus adjuvanted influenza vaccine: A retrospective cohort study. Vaccine.
165		2020;38:372–379.
166	[5]	Abreu RB, Clutter EF, Attari S, et al. IgA Responses Following Recurrent Influenza
167		Virus Vaccination. Frontiers in Immunology. 2020;11:902.
168	[6]	Carlock MA, Ingram JG, Clutter EF, et al. Impact of age and pre-existing immunity
169		on the induction of human antibody responses against influenza B viruses. Human
170		Vaccines & Immunotherapeutics. 2019;15:2030–2043.
171	[7]	Price AM, Flannery B, Talbot HK, et al. Influenza Vaccine Effectiveness Against
172		Influenza A(H3N2)-Related Illness in the United States During the 2021 Influenza
173		Season. Clinical Infectious Diseases. 2023;76:1358–1363.

- 174 [8] Erbelding EJ, Post DJ, Stemmy EJ, et al. A Universal Influenza Vaccine: The Strategic
- 175 Plan for the National Institute of Allergy and Infectious Diseases. The Journal of
- 176 Infectious Diseases. 2018;218:347–354.